KULR Technology Group Awarded 5-year Preferred Battery Supply Agreement from Caban Energy; Expands U.S. Manufacturing Footprint

KULR Technology Group Awarded 5-year Preferred Battery Supply Agreement from Caban Energy; Expands U.S. Manufacturing Footprint

HOUSTON, Jan. 14, 2026 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), an energy-systems platform company that enables the safe, certifiable deployment of ultra-high-power lithium battery systems for space and defense programs, hyperscale AI data centers, and telecom infrastructure OEMs, today announced it was awarded a five‑year preferred battery supply agreement from Caban Energy (“Caban”), a Miami-based renewable energy services and technology company delivering flexible solutions for critical infrastructure. The agreement, generating an estimated $30 million in total revenue to KULR starting 2026, further reinforces KULR’s strategy to deliver mission‑critical energy‑storage technologies across digital infrastructure, communications, aerospace, and defense markets, while expanding U.S.‑based manufacturing capacity to support growing customer demand.

KULR Caban Lockout

KULR’s expansion into lithium-based battery solutions for digital infrastructure and telecommunications underscores the increasingly central role of advanced energy storage in ensuring continuous, mission-critical network operations. In telecom environments, batteries serve as the primary line of defense against grid interruptions – preserving network availability, minimizing service outages, and sustaining communications during emergency conditions as expectations for uptime and resilience continue to rise. By integrating telecom-focused battery solutions into its portfolio, KULR is aligning its technology platform with the evolving requirements of digital infrastructure operators who require reliable, high-performance backup power to support 5G rollouts and long-term network scalability.

As part of the agreement, the Company took over Caban’s Plano, Texas‑based manufacturing assets, strengthening KULR’s domestic production footprint and accelerating its expansion into communications, fiber, and data‑center energy‑storage markets across the United States.

“This supplier award and the addition of manufacturing assets are timely and important steps as we continue to scale into fast‑growing global markets,” said Michael Mo, Chief Executive Officer of KULR Technology Group. “By centralizing and integrating these capabilities into our U.S. manufacturing operations, we expect to increase development and production throughput and deliver high‑reliability energy systems at the scale required by our customers.”

Caban focuses on decarbonizing energy for critical infrastructure, including telecommunications networks and other mission‑critical facilities. A core component of Caban’s commercial model is Energy‑as‑a‑Service (EaaS), through which the company installs, operates, and owns renewable energy infrastructure while customers pay a predictable monthly fee without upfront capital expenditure. Caban’s EaaS offerings are designed to lower operating costs, reduce carbon footprint, eliminate risk exposure, and improve the reliability and predictability of energy supply. The company has experienced strong momentum in recent years, forging key partnerships and securing long-term contracts with some of the largest telecommunications companies in the world, including a new project with Digicel announced earlier this year. Its solutions have been successfully deployed across 12 countries, enabling businesses to enhance their energy resilience while meeting ambitious sustainability goals.

About KULR Technology Group, Inc.
KULR Technology Group, Inc. (NYSE American: KULR) is an energy-management and reliability platform company delivering certifiable battery safety, vibration-mitigation, and thermal control solutions that enable ultra-high-power lithium-ion systems and sensitive electronics to operate reliably across space and defense missions, hyperscale AI data centers, telecom infrastructure and mobility applications.

About Caban
Caban, founded in 2018, set out to tackle the challenge of decarbonizing one of the most fossil fuel-dependent industries. Initially focused on providing alternative energy solutions for the telecommunications industry in the Americas, the company has demonstrated success in supplying energy to several of the world’s largest telecom operators. Building on this momentum, Caban has scaled globally and expanded its reach to support clean energy needs across critical infrastructure sectors worldwide. Caban uniquely combines service, hardware, software, and finance tools to deliver reliable, clean power and boosts your bottom line. This turnkey approach allows clients to work directly with one trusted partner to achieve reliability and decarbonization across their operations.

For more information, visit www.cabanenergy.com.

Safe Harbor Statement
This release contains certain forward-looking statements based on our current expectations, forecasts and assumptions that involve risks and uncertainties. Forward-looking statements in this release are based on information available to us as of the date hereof. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our Form 10-K filed with the Securities and Exchange Commission on March 31, 2025, as may be amended or supplemented by other reports we file with the Securities and Exchange Commission from time to time. Forward-looking statements include statements regarding our expectations, beliefs, intentions, or strategies regarding the future and can be identified by forward-looking words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” and “would” or similar words. All forecasts are provided by management in this release are based on information available at this time and management expects that internal projections and expectations may change over time. In addition, the forecasts are entirely based on management’s best estimate of our future financial performance given our current contracts, current backlog of opportunities and conversations with new and existing customers about our products and services. We assume no obligation to update the information included in this press release, whether as a result of new information, future events or otherwise.

Investor Relations:
KULR Technology Group, Inc.
Phone: 858-866-8478 x 847
Email: ir@kulr.ai

KULR Media Relations:
M Group Strategic Communications (on behalf of KULR)
Email: kulr@mgroupsc.com

A photo accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/0b2da4ec-b5ec-46a6-8af2-19f9fac9a770

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

Source link

admin Precision Manufacturing News Biologics manufacturing Maryland Samsung scale U.S

Samsung Biologics looks to scale up U.S. manufacturing in Maryland

Samsung Biologics CEO John Rim delivers his keynote speech outlining the company’s future roadmap at the 44th J.P. Morgan Health Care Conference held at Westin St. Francis Hotel in San Francisco on Jan. 13. [SAMSUNG BIOLOGICS]

SAN FRANCISCO — Samsung Biologics is seeking to strengthen its U.S. footprint by expanding capacity at its recently acquired manufacturing facility in Rockville, Maryland, as it seeks to meet growing customer demand for U.S.-based production amid shifting trade policies.

“The GSK facility acquisition is anticipated to close in March this year, giving us regional presentation in the United States,” said CEO John Rim at the 44th J.P. Morgan Health Care Conference on Tuesday. “It will have flexibility to take on additional products beyond the GSK product line.”

Samsung Biologics announced in December 2025 that it would acquire the Rockville facility from GlaxoSmithKline for $280 million. The plant has an annual production capacity of 60,000 liters (15,850 gallons).

“It [the U.S. factory] has always been a higher cost area and everybody knows that, but for us, the U.S. was critical and the reason for that is we’ve lost customers because we didn’t have a U.S. presence,” Rim said, adding that clients wanted supply chain resiliency.

While the Rockville facility is modest in scale compared to Samsung Biologics’ five plants in Songdo, Korea — which together have a combined capacity of 785,000 liters — the company said the U.S. site can be expanded by an additional 20,000 to 40,000 liters.

“Everybody understands that there’s some pricing flexibility, so we’ll have to work through,” Rim said. “But we do see that having the Rockfield facility will open up new venues of growth for us.”

Initially, the plant will continue manufacturing existing GSK products, including Benlysta, a monoclonal antibody treatment for lupus. Over time, the facility is expected to be upgraded to support multiple modalities, particularly antibody production.

Samsung Biologics CEO John Rim delivers his keynote speech outlining the company's future roadmap at the 44th J.P. Morgan Health Care Conference held at Westin St. Francis Hotel in San Francisco on Jan. 13. [SAMSUNG BIOLOGICS]

“Whether antibody drug conjugate [ADC] capabilities are added in the future will depend on demand,” Rim added at a separate press conference held with the Korean press on Monday.

With the facility, the Korean company will have more than 500 employees working at the site, and plans to recruit more U.S talent in the future.

The company’s main production site, however, remains rooted in its Songdo campus as U.S. tariffs on biopharmaceutical imports have largely dissolved. While tariffs were previously discussed at levels as high as 250 percent, subsequent bilateral negotiations have capped potential tariffs at 15 percent, significantly reducing trade-related risk.

In parallel, Samsung Biologics is continuing to expand domestically. Construction of a sixth plant is expected to begin between 2026 and 2027, and the company has secured land for a third phase of its Songdo manufacturing campus. It plans to invest approximately 7 trillion won ($4.7 billion) through 2034 to build additional production facilities.

Looking ahead, Rim said the company’s investment strategy, including mergers and acquisitions, will remain focused on antibody manufacturing.

The global biopharmaceutical market is projected to grow at a compound annual growth rate of 10 percent, from $565 billion in 2025 to $921 billion in 2030, according to market researcher Evaluate Pharma, driven in particular by monoclonal antibodies, multispecific antibodies, ADCs and fusion proteins.

“The antibody market is so large that even single-digit growth translates into meaningful demand,” Rim said. “Other segments may grow faster in percentage terms, but their overall impact is limited by smaller market size.”

Samsung Biologics is also closely monitoring developments in GLP-1 therapies — particularly the shift toward oral formulations — as well as opportunities in peptide manufacturing.

The company has rebranded its contract manufacturing offering under the name ExcellenS, a move that reflects its emphasis on tailored production and operational efficiency, based on standardized and scalable manufacturing processes.

Samsung Biologics is scheduled to report its fourth-quarter and full-year 2025 earnings on Jan. 21. The company recorded a record annual order intake of 6.8 trillion won in 2025, with cumulative orders surpassing $21 billion.